Consensus guidelines for the use and interpretation of angiogenesis assays

References 714

1. 1.

   Bikfalvi A. History and conceptual developments in vascular biology and angiogenesis research: a personal view. Angiogenesis. 2017;20(4):463-478.

   Not in our library10.1007/s10456-017-9569-2

2. 2.

   Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-427.

   Not in our library10.1038/nrd3455

3. 3.

   Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52(2):237-268.

   Not in our library

4. 4.

   Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409-426.

   Not in our library10.1007/s10456-017-9562-9

5. 5.

   De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457-474.

   Not in our library10.1038/nrc.2017.51

6. 6.

   Craig MP, Sumanas S. ETS transcription factors in embryonic vascular development. Angiogenesis. 2016;19(3):275-285.

   Not in our library10.1007/s10456-016-9511-z

7. 7.

   Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, Koblar S, Harvey NL, Lopez AF, Shackleton M, Bonder CS. A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis. 2016;19(4):463-486.

   Not in our library10.1007/s10456-016-9520-y

8. 8.

   Loegl J, Nussbaumer E, Hiden U, Majali-Martinez A, Ghaffari-Tabrizi-Wizy N, Cvitic S, Lang I, Desoye G, Huppertz B. Pigment epithelium-derived factor (PEDF): a novel trophoblast-derived factor limiting feto-placental angiogenesis in late pregnancy. Angiogenesis. 2016;19(3):373-388.

   Not in our library10.1007/s10456-016-9513-x

9. 9.

   Dings RP, Chen X, Hellebrekers DM, van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH. Design of nonpeptidic topo-mimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst. 2006;98(13):932-936.

   Not in our library10.1093/jnci/djj247

10. 10.

    MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis. 2016;19(3):389-406.

    Not in our library10.1007/s10456-016-9515-8

11. 11.

    Zhi K, Li M, Bai J, Wu Y, Zhou S, Zhang X, Qu L. Quercitrin treatment protects endothelial progenitor cells from oxidative damage via inducing autophagy through extracellular signal-regulated kinase. Angiogenesis. 2016;19(3):311-324.

    Not in our library10.1007/s10456-016-9504-y

12. 12.

    Conway RE, Rojas C, Alt J, Novakova Z, Richardson SM, Rodrick TC, Fuentes JL, Richardson NH, Attalla J, Stewart S, Fahmy B, Barinka C, Ghosh M, Shapiro LH, Slusher BS. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis. 2016;19(4):487-500.

    Not in our library10.1007/s10456-016-9521-x

13. 13.

    Gao JH, Wen SL, Feng S, Yang WJ, Lu YY, Tong H, Liu R, Tang SH, Huang ZY, Tang YM, Yang JH, Xie HQ, Tang CW. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis. 2016;19(4):501-511.

    Not in our library10.1007/s10456-016-9522-9

14. 14.

    Lu K, Bhat M, Basu S. Plants and their active compounds: natural molecules to target angiogenesis. Angiogenesis. 2016;19(3):287-295.

    Not in our library10.1007/s10456-016-9512-y

15. 15.

    Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis. 2017;20(2):205-215.

    Not in our library10.1007/s10456-017-9550-0

16. 16.

    Hamming LC, Slotman BJ, Verheul HMW, Thijssen VL. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis. 2017;20(2):217-232.

    Not in our library10.1007/s10456-017-9546-9

17. 17.

    Bani M, Decio A, Giavazzi R, Ghilardi C. Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. Angiogenesis. 2017;20(2):233-241.

    Not in our library10.1007/s10456-017-9549-6

18. 18.

    Berndsen RH, Abdul UK, Weiss A, Zoetemelk M, Te Winkel MT, Dyson PJ, Griffioen AW, Nowak-Sliwinska P. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Angiogenesis. 2017;20(2):245-267.

    Not in our library10.1007/s10456-017-9551-z

19. 19.

    van Beijnum JR, Nowak-Sliwinska P, van Berkel M, Wong TJ, Griffioen AW. A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7). Angiogenesis. 2017;20(4):641-654.

    Not in our library10.1007/s10456-017-9576-3

20. 20.

    Griffioen AW, Weiss A, Berndsen RH, Abdul UK, te Winkel MT, Nowak-Sliwinska P. The emerging quest for the optimal angiostatic combination therapy. Biochem Soc Trans. 2014;42(6):1608-1615.

    Not in our library10.1042/bst20140193

21. 21.

    Ochsenbein AM, Karaman S, Proulx ST, Goldmann R, Chittazhathu J, Dasargyri A, Chong C, Leroux JC, Stanley ER, Detmar M. Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling. Angiogenesis. 2016;19(4):513-524.

    Not in our library10.1007/s10456-016-9523-8

22. 22.

    Martinez-Corral I, Stanczuk L, Frye M, Ulvmar MH, Dieguez-Hurtado R, Olmeda D, Makinen T, Ortega S. Vegfr3-CreER (T2) mouse, a new genetic tool for targeting the lymphatic system. Angiogenesis. 2016;19(3):433-445.

    Not in our library10.1007/s10456-016-9505-x

23. 23.

    Zhang R, Han Z, Degos V, Shen F, Choi EJ, Sun Z, Kang S, Wong M, Zhu W, Zhan L, Arthur HM, Oh SP, Faughnan ME, Su H. Persistent infiltration and pro-inflammatory differentiation of monocytes cause unresolved inflammation in brain arteriovenous malformation. Angiogenesis. 2016;19(4):451-461.

    Not in our library10.1007/s10456-016-9519-4

24. 24.

    Tattersal IW, Cuervo H. Vascular biology 2014 in Monterey, California: celebrating 20 years of NAVBO. Vasc Cell. 2014;6:25.

    Not in our library10.1186/s13221-014-0025-4

25. 25.

    Hillen F, Baeten CI, van de Winkel A, Creytens D, van der Schaft DW, Winnepenninckx V, Griffioen AW. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother CII. 2008;57(1):97-106.

    Not in our library10.1007/s00262-007-0353-9

26. 26.

    von Stillfried S, Apitzsch JC, Ehling J, Penzkofer T, Mahnken AH, Knuchel R, Floege J, Boor P. Contrast-enhanced CT imaging in patients with chronic kidney disease. Angiogenesis. 2016;19(4):525-535.

    Not in our library10.1007/s10456-016-9524-7

27. 27.

    Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011;17(23):7337-7346.

    Not in our library10.1158/1078-0432.ccr-11-1667

28. 28.

    van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 2015;67(2):441-461.

    Not in our library10.1124/pr.114.010215

29. 29.

    Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Res Updat. 2016;25:26-37.

    Not in our library10.1016/j.drup.2016.02.002

30. 30.

    Williams PA, Silva EA. The role of synthetic extracellular matrices in endothelial progenitor cell homing for treatment of vascular disease. Ann Biomed Eng. 2015;43(10):2301-2313.

    Not in our library10.1007/s10439-015-1400-x

31. 31.

    Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res. 2013;112(9):1288-1302.

    Not in our library10.1161/circresaha.113.300565

32. 32.

    Mistriotis P, Andreadis ST. Vascular aging: molecular mechanisms and potential treatments for vascular rejuvenation. Ageing Res Rev. 2017;37:94-116.

    Not in our library10.1016/j.arr.2017.05.006

33. 33.

    Donato AJ, Morgan RG, Walker AE, Lesniewski LA. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol. 2015;89(Pt B):122-135.

    Not in our library10.1016/j.yjmcc.2015.01.021

34. 34.

    Vitorino P, Meyer T. Modular control of endothelial sheet migration. Genes Dev. 2008;22(23):3268-3281.

    Not in our library10.1101/gad.1725808

35. 35.

    Costa G, Harrington KI, Lovegrove HE, Page DJ, Chakravartula S, Bentley K, Herbert SP. Asymmetric division coordinates collective cell migration in angiogenesis. Nat Cell Biol. 2016;18(12):1292-1301.

    Not in our library10.1038/ncb3443

36. 36.

    Hamm MJ, Kirchmaier BC, Herzog W. Sema3d controls collective endothelial cell migration by distinct mechanisms via Nrp1 and PlxnD1. J Cell Biol. 2016;215(3):415-430.

    Not in our library10.1083/jcb.201603100

37. 37.

    Haeger A, Wolf K, Zegers MM, Friedl P. Collective cell migration: guidance principles and hierarchies. Trends Cell Biol. 2015;25(9):556-566.

    Not in our library10.1016/j.tcb.2015.06.003

38. 38.

    Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation. 2000;102(2):185-190.

    Not in our library10.1161/01.cir.102.2.185

39. 39.

    Tchaikovski V, Olieslagers S, Bohmer FD, Waltenberger J. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation. 2009;120(2):150-159.

    Not in our library10.1161/circulationaha.108.817528

40. 40.

    Tchaikovski V, Tchaikovski S, Olieslagers S, Waltenberger J. Monocyte dysfunction as a previously unrecognized pathophysiologically relevant component of hyperlipidemic ApoE−/− mice contributing to atherogenesis and impaired arteriogenesis. Int J Cardiol. 2015;190:214-216.

    Not in our library10.1016/j.ijcard.2015.04.188

Cited by papers we hold 11

• Pathological angiogenesis: mechanisms and therapeutic strategies · 2023
  No notice
• Umbilical Cord Blood-Derived Exosomes From Very Preterm Infants With Bronchopulmonary Dysplasia Impaired Endothelial Angiogenesis: Roles of Exosomal MicroRNAs · 2021
  Not checked
• Anti-Angiogenic Therapy: Current Challenges and Future Perspectives · 2021
  No notice
• M2 Macrophage-Derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2 · 2021
  No notice
• The role of long noncoding RNAs in ischaemic stroke · 2020
  Not checked
• The Importance of Mechanical Forces for in vitro Endothelial Cell Biology · 2020
  No notice
• Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay” · 2020
  No notice
• The role of glycolysis and mitochondrial respiration in the formation and functioning of endothelial tip cells during angiogenesis · 2019
  No notice
• Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function · 2019
  No notice
• Tumor angiogenesis: causes, consequences, challenges and opportunities · 2019
  No notice
• Unraveling the Role of Angiogenesis in Cancer Ecosystems · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.